Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting February 28, 20190CommentsEN Read More
Oxurion NV to Present at the 2019 BIO CEO & Investor Conference February 4, 20190CommentsEN Read More
Oxurion NV to Present at 2019 Biotech Showcase Conference and Participate in CEO Power Breakfast Roundtable during the 37th Annual J.P. Morgan Healthcare Conference December 19, 20180CommentsEN Read More
Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD November 5, 20180CommentsEN Read More
Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors October 29, 20180CommentsEN Read More
Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting October 24, 20180CommentsEN Read More
Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project October 22, 20180CommentsEN Read More
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) September 20, 20180CommentsEN Read More
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) September 20, 20180CommentsEN Read More
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria September 17, 20180CommentsEN Read More
Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website September 10, 20180CommentsEN Read More
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) July 19, 20180CommentsEN Read More
